INSPECS Group plc (AIM:SPEC)
London · Delayed Price · Currency is GBP · Price in GBX 47.50
+0.60 (1.26%)
Aug 15, 2025, 4:35 PM GMT+1
INSPECS Group Revenue
In the year 2024, INSPECS Group had annual revenue of 198.26M GBP, down -2.48%. INSPECS Group had revenue of 95.21M in the half year ending December 31, 2024, a decrease of -0.97%.
Revenue
198.26M
Revenue Growth
-2.48%
P/S Ratio
0.24
Revenue / Employee
119.87K
Employees
1,654
Market Cap
48.29M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 198.26M | -5.03M | -2.48% |
| Dec 31, 2023 | 203.29M | 2.34M | 1.16% |
| Dec 31, 2022 | 200.96M | 18.93M | 10.40% |
| Dec 31, 2021 | 182.02M | 147.30M | 424.13% |
| Dec 31, 2020 | 34.73M | -11.52M | -24.90% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 41.24B |
| GSK plc | 31.63B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| ConvaTec Group | 1.72B |
| Hikma Pharmaceuticals | 2.35B |
| HUTCHMED (China) | 439.54M |
| Oxford Nanopore Technologies | 183.19M |